JP2014110810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014110810A5 JP2014110810A5 JP2014049395A JP2014049395A JP2014110810A5 JP 2014110810 A5 JP2014110810 A5 JP 2014110810A5 JP 2014049395 A JP2014049395 A JP 2014049395A JP 2014049395 A JP2014049395 A JP 2014049395A JP 2014110810 A5 JP2014110810 A5 JP 2014110810A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- antibody
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 208000028867 ischemia Diseases 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 230000024203 complement activation Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021137 Hypovolaemia Diseases 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 206010061372 Streptococcal infection Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 201000005311 drug allergy Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 102000003706 Complement factor D Human genes 0.000 claims 1
- 108090000059 Complement factor D Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85650506P | 2006-11-02 | 2006-11-02 | |
| US60/856,505 | 2006-11-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235325A Division JP2013027404A (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015171685A Division JP2015214591A (ja) | 2006-11-02 | 2015-09-01 | ヒト化抗ｄ因子抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014110810A JP2014110810A (ja) | 2014-06-19 |
| JP2014110810A5 true JP2014110810A5 (https=) | 2014-07-31 |
| JP5918794B2 JP5918794B2 (ja) | 2016-05-18 |
Family
ID=39345075
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535444A Withdrawn JP2010508819A (ja) | 2006-11-02 | 2007-10-31 | ヒト化抗ｄ因子抗体 |
| JP2012235325A Pending JP2013027404A (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
| JP2012235324A Expired - Fee Related JP5474158B2 (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
| JP2014049395A Active JP5918794B2 (ja) | 2006-11-02 | 2014-03-12 | ヒト化抗ｄ因子抗体 |
| JP2015171685A Withdrawn JP2015214591A (ja) | 2006-11-02 | 2015-09-01 | ヒト化抗ｄ因子抗体 |
| JP2017157499A Pending JP2017200492A (ja) | 2006-11-02 | 2017-08-17 | ヒト化抗ｄ因子抗体 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535444A Withdrawn JP2010508819A (ja) | 2006-11-02 | 2007-10-31 | ヒト化抗ｄ因子抗体 |
| JP2012235325A Pending JP2013027404A (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
| JP2012235324A Expired - Fee Related JP5474158B2 (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015171685A Withdrawn JP2015214591A (ja) | 2006-11-02 | 2015-09-01 | ヒト化抗ｄ因子抗体 |
| JP2017157499A Pending JP2017200492A (ja) | 2006-11-02 | 2017-08-17 | ヒト化抗ｄ因子抗体 |
Country Status (35)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4764590B2 (ja) * | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| SG10201804008UA (en) * | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| TW201716437A (zh) * | 2006-11-02 | 2017-05-16 | 建南德克公司 | 人類化之抗-因子ｄ抗體及其用途 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG190572A1 (en) * | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| TW201006485A (en) * | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2726087A1 (en) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CN102149825B (zh) * | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| US8918657B2 (en) | 2008-09-08 | 2014-12-23 | Virginia Tech Intellectual Properties | Systems, devices, and/or methods for managing energy usage |
| EP2391652A4 (en) | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| KR20110020642A (ko) | 2009-08-24 | 2011-03-03 | 삼성전자주식회사 | 사용자 접근을 인식하여 반응하는 ｇｕｉ제공 장치 및 방법 |
| WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| KR20120104542A (ko) | 2009-10-15 | 2012-09-21 | 아보트 러보러터리즈 | Ｉｌ?１ 결합 단백질 |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20110165648A1 (en) * | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| EP3252072A3 (en) * | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| PE20141060A1 (es) | 2010-12-21 | 2014-09-26 | Abbvie Inc | Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso |
| PT2661433T (pt) | 2011-01-04 | 2017-10-24 | Novartis Ag | Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd) |
| TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| US9815819B2 (en) | 2012-06-28 | 2017-11-14 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN104379579B (zh) | 2012-06-28 | 2017-03-08 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| WO2014002058A2 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
| ES2644700T3 (es) | 2012-06-28 | 2017-11-30 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la ruta del complemento |
| EP2867225B1 (en) | 2012-06-28 | 2017-08-09 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| UY34905A (es) | 2012-07-12 | 2014-01-31 | Abbvie Inc | Proteínas de unión a il-1 |
| CA2882724A1 (en) | 2012-07-12 | 2014-01-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| CN104662161A (zh) | 2012-09-19 | 2015-05-27 | 弗·哈夫曼-拉罗切有限公司 | 用于防止正亮氨酸错误地掺入蛋白质中的方法和组合物 |
| TW202037609A (zh) | 2012-11-01 | 2020-10-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
| WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
| SG11201601044XA (en) * | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
| AU2015253042A1 (en) | 2014-05-01 | 2016-10-20 | Genentech, Inc. | Anti-factor D antibody variants and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| AU2016344133A1 (en) * | 2015-10-30 | 2018-05-17 | Genentech, Inc. | Anti-Factor D antibody formulations |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| MY196448A (en) | 2015-10-30 | 2023-04-12 | Genentech Inc | Anti-Htra1 Antibodies and Methods of use Thereof |
| CN108513585A (zh) | 2015-10-30 | 2018-09-07 | 豪夫迈·罗氏有限公司 | 测量因子d活性和因子d抑制剂效力的方法 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017127761A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| US12297266B2 (en) | 2016-04-18 | 2025-05-13 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| US11155617B2 (en) | 2016-06-23 | 2021-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
| US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| AU2018217720A1 (en) | 2017-02-10 | 2019-09-05 | The Trustees Of The University Of Pennsylvania | Anti-factor D antibodies and uses thereof |
| CN106905431B (zh) * | 2017-04-10 | 2020-01-17 | 旭华（上海）生物研发中心有限公司 | 抗人补体d因子的单克隆抗体及其用途 |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| FR3071483B1 (fr) * | 2017-09-27 | 2020-11-27 | Airbus Operations Sas | Systeme de surveillance de braquage d'une roulette de train d'atterrissage d'un aeronef |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| US11166910B2 (en) | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| CN110240652B (zh) * | 2019-06-05 | 2022-09-06 | 百奥泰生物制药股份有限公司 | 抗补体d因子抗体及其应用 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2022215054A1 (en) * | 2021-04-09 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
| CN119176879B (zh) * | 2024-09-05 | 2025-08-05 | 西安市中心血站（陕西省血液中心） | 一种中和抗d抗体的抗独特型抗体及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| US5861156A (en) | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
| US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| DE69533921T2 (de) | 1994-03-23 | 2005-12-01 | Alexion Pharmaceuticals, Inc., New Haven | Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5897475A (en) | 1994-10-05 | 1999-04-27 | Antex Biologics, Inc. | Vaccines comprising enhanced antigenic helicobacter spp. |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
| US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
| NZ503033A (en) | 1997-08-26 | 2003-01-31 | Gliatech Inc | Inhibition of complement activation using anti-properdin agents |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| ATE410512T1 (de) | 1997-11-21 | 2008-10-15 | Genentech Inc | Plättchen-spezifische antigene und deren pharmazeutische verwendung |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| JP4437192B2 (ja) | 1998-02-20 | 2010-03-24 | タノックス インコーポレイテッド | 補体活性化阻害剤 |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| AU5587799A (en) | 1998-08-27 | 2000-03-21 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
| CA2348757A1 (en) | 1998-12-16 | 2000-06-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| ES2327785T3 (es) | 1998-12-22 | 2009-11-03 | Genentech, Inc. | Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas. |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2362427A1 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP4836329B2 (ja) | 1999-03-11 | 2011-12-14 | メルク セローノ エス．エイ． | 血管接着分子およびその機能の調節 |
| US6642353B1 (en) | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
| EP1234030A4 (en) | 1999-11-19 | 2003-05-07 | Human Genome Sciences Inc | 18 HUMANE SECRETIED PROTEINS |
| CA2491433A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6998468B2 (en) * | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| JP4764590B2 (ja) | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| EP2896631A1 (en) | 2000-10-10 | 2015-07-22 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| PL366307A1 (en) | 2000-10-13 | 2005-01-24 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
| ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| AU2003258714A1 (en) | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| RU2232991C1 (ru) * | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7923010B2 (en) | 2003-09-11 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| JP2008520242A (ja) | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
| WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| US7745389B2 (en) | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| FI118793B (fi) * | 2005-07-11 | 2008-03-31 | Olli Friman | Rullaluistimen pyörän vierintälaakerin suojalevy |
| EP2662089A3 (en) | 2005-10-08 | 2014-02-19 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| SG10201804008UA (en) | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| US7941135B2 (en) | 2006-03-22 | 2011-05-10 | Alcatel-Lucent Usa Inc. | Methods of performing live monitoring of a wireless communication network |
| TW201716437A (zh) | 2006-11-02 | 2017-05-16 | 建南德克公司 | 人類化之抗-因子ｄ抗體及其用途 |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
-
2007
- 2007-10-31 TW TW105127533A patent/TW201716437A/zh unknown
- 2007-10-31 RS RS20181476A patent/RS58233B1/sr unknown
- 2007-10-31 MY MYPI20091788A patent/MY157948A/en unknown
- 2007-10-31 CA CA2939806A patent/CA2939806A1/en not_active Abandoned
- 2007-10-31 KR KR1020097011297A patent/KR20090078364A/ko not_active Withdrawn
- 2007-10-31 NZ NZ576812A patent/NZ576812A/en not_active IP Right Cessation
- 2007-10-31 MX MX2009004665A patent/MX2009004665A/es active IP Right Grant
- 2007-10-31 KR KR1020157009721A patent/KR101645144B1/ko not_active Expired - Fee Related
- 2007-10-31 CN CN201610570520.5A patent/CN106188299A/zh active Pending
- 2007-10-31 EP EP15151317.3A patent/EP2907827B1/en active Active
- 2007-10-31 UA UAA200905597A patent/UA101603C2/ru unknown
- 2007-10-31 KR KR1020167020466A patent/KR20160092061A/ko not_active Ceased
- 2007-10-31 PL PL15151317T patent/PL2907827T3/pl unknown
- 2007-10-31 CN CN201610570104.5A patent/CN106084055A/zh active Pending
- 2007-10-31 LT LTEP15151317.3T patent/LT2907827T/lt unknown
- 2007-10-31 SI SI200731587T patent/SI2097455T1/sl unknown
- 2007-10-31 TW TW107108695A patent/TW201843170A/zh unknown
- 2007-10-31 PT PT15151317T patent/PT2907827T/pt unknown
- 2007-10-31 ES ES15151317T patent/ES2700609T3/es active Active
- 2007-10-31 KR KR1020197000043A patent/KR20190003860A/ko not_active Ceased
- 2007-10-31 DK DK15151317.3T patent/DK2907827T3/da active
- 2007-10-31 SI SI200732083T patent/SI2907827T1/sl unknown
- 2007-10-31 RU RU2009120699A patent/RU2474589C9/ru not_active IP Right Cessation
- 2007-10-31 AR ARP070104846A patent/AR063760A1/es not_active Application Discontinuation
- 2007-10-31 TW TW096141085A patent/TWI391401B/zh not_active IP Right Cessation
- 2007-10-31 PE PE2012000037A patent/PE20121034A1/es active IP Right Grant
- 2007-10-31 CN CN201610570481.9A patent/CN106188304A/zh active Pending
- 2007-10-31 NZ NZ596042A patent/NZ596042A/xx not_active IP Right Cessation
- 2007-10-31 UA UAA201214158A patent/UA116614C2/uk unknown
- 2007-10-31 DK DK07868632.6T patent/DK2097455T3/en active
- 2007-10-31 EP EP12152860A patent/EP2471818A1/en not_active Ceased
- 2007-10-31 EP EP07868632.6A patent/EP2097455B1/en active Active
- 2007-10-31 JP JP2009535444A patent/JP2010508819A/ja not_active Withdrawn
- 2007-10-31 CL CL200703161A patent/CL2007003161A1/es unknown
- 2007-10-31 PE PE2007001490A patent/PE20081259A1/es active IP Right Grant
- 2007-10-31 BR BRPI0716299-5A2A patent/BRPI0716299A2/pt active Search and Examination
- 2007-10-31 US US11/931,060 patent/US8067002B2/en not_active Expired - Fee Related
- 2007-10-31 CA CA2667997A patent/CA2667997C/en not_active Expired - Fee Related
- 2007-10-31 KR KR1020147019915A patent/KR20140101873A/ko not_active Withdrawn
- 2007-10-31 TW TW100142121A patent/TWI472535B/zh not_active IP Right Cessation
- 2007-10-31 MY MYPI2013002530A patent/MY183804A/en unknown
- 2007-10-31 PT PT78686326T patent/PT2097455E/pt unknown
- 2007-10-31 EP EP18190268.5A patent/EP3466971A1/en not_active Withdrawn
- 2007-10-31 WO PCT/US2007/083172 patent/WO2008055206A2/en not_active Ceased
- 2007-10-31 CN CN201510511513.3A patent/CN105085682A/zh active Pending
- 2007-10-31 ES ES07868632.6T patent/ES2525477T3/es active Active
- 2007-10-31 KR KR1020177026557A patent/KR20170110727A/ko not_active Ceased
- 2007-10-31 CN CN201610570102.6A patent/CN106084054A/zh active Pending
- 2007-10-31 CN CN200780048936.XA patent/CN101589063B/zh not_active Expired - Fee Related
- 2007-10-31 PL PL07868632T patent/PL2097455T3/pl unknown
- 2007-10-31 AU AU2007313685A patent/AU2007313685C1/en not_active Ceased
- 2007-10-31 CN CN201610569910.0A patent/CN106188303A/zh active Pending
- 2007-10-31 TW TW103141058A patent/TW201534620A/zh unknown
- 2007-10-31 NZ NZ609813A patent/NZ609813A/en not_active IP Right Cessation
-
2009
- 2009-05-03 IL IL198512A patent/IL198512A/en active IP Right Review Request
- 2009-05-05 ZA ZA2009/03088A patent/ZA200903088B/en unknown
- 2009-05-26 CR CR10827A patent/CR10827A/es unknown
- 2009-05-29 CO CO09055632A patent/CO6190543A2/es active IP Right Grant
- 2009-05-29 NO NO20092121A patent/NO20092121L/no not_active Application Discontinuation
- 2009-06-01 MA MA31941A patent/MA30962B1/fr unknown
- 2009-06-02 EC EC2009009379A patent/ECSP099379A/es unknown
-
2011
- 2011-01-14 US US13/007,142 patent/US8187604B2/en not_active Expired - Fee Related
- 2011-01-14 US US13/007,061 patent/US8193329B2/en not_active Expired - Fee Related
-
2012
- 2012-05-01 US US13/461,253 patent/US8372403B2/en not_active Expired - Fee Related
- 2012-10-25 JP JP2012235325A patent/JP2013027404A/ja active Pending
- 2012-10-25 JP JP2012235324A patent/JP5474158B2/ja not_active Expired - Fee Related
- 2012-11-06 RU RU2012147286A patent/RU2678802C2/ru not_active IP Right Cessation
-
2013
- 2013-02-05 ZA ZA2013/00949A patent/ZA201300949B/en unknown
- 2013-02-05 US US13/759,613 patent/US8753826B2/en not_active Expired - Fee Related
-
2014
- 2014-03-12 JP JP2014049395A patent/JP5918794B2/ja active Active
- 2014-05-20 US US14/282,063 patent/US20140303355A1/en not_active Abandoned
-
2015
- 2015-04-29 IL IL238517A patent/IL238517B/en active IP Right Grant
- 2015-04-29 AR ARP150101290A patent/AR100225A2/es unknown
- 2015-07-06 US US14/792,213 patent/US20160002352A1/en not_active Abandoned
- 2015-07-06 US US14/792,236 patent/US20160002353A1/en not_active Abandoned
- 2015-07-06 US US14/792,197 patent/US20150376295A1/en not_active Abandoned
- 2015-08-12 PH PH12015501763A patent/PH12015501763A1/en unknown
- 2015-09-01 JP JP2015171685A patent/JP2015214591A/ja not_active Withdrawn
-
2016
- 2016-03-29 HK HK16103589.3A patent/HK1215712A1/zh unknown
- 2016-07-29 US US15/224,366 patent/US20170166630A1/en not_active Abandoned
- 2016-12-23 HK HK16114632.7A patent/HK1226417A1/zh unknown
-
2017
- 2017-08-17 JP JP2017157499A patent/JP2017200492A/ja active Pending
- 2017-08-24 IL IL254137A patent/IL254137A0/en unknown
-
2018
- 2018-11-23 HR HRP20181969TT patent/HRP20181969T1/hr unknown
-
2019
- 2019-01-29 RU RU2019102393A patent/RU2019102393A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014110810A5 (https=) | ||
| JP2013027404A5 (https=) | ||
| RU2019102393A (ru) | Гуманизированные антитела к фактору d и их применения | |
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| AU2015279128B2 (en) | Multispecific antibody constructs | |
| JP2017522903A5 (https=) | ||
| JP2018502060A5 (https=) | ||
| JP2016196468A5 (https=) | ||
| JP2018512856A5 (https=) | ||
| JP2017529097A5 (https=) | ||
| JP2016524592A5 (https=) | ||
| JP2014518883A5 (https=) | ||
| JP2018520139A (ja) | エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法 | |
| JP2011514150A5 (https=) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2014526898A5 (https=) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2018102798A (ru) | Антитела к фактору xi и способы их применения | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2016525502A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2019504822A5 (https=) | ||
| CN104507964A (zh) | P2x7受体拮抗剂和激动剂 | |
| JP2016530223A5 (https=) | ||
| JP2014506259A5 (https=) |